Skip to main content
. 2023 May 2;299(6):104779. doi: 10.1016/j.jbc.2023.104779

Figure 6.

Figure 6

DNA hypomethylating agents modulate hepatic macrophage autophagy in NAFLD mice.A, mRNA expression of DNMT1 in the macrophage derived from Aza (0.25 mg/kg) and Zeb (200 mg/kg)-treated mice. B, mRNA expression of LC3B, ATG5, and ATG7 in different groups indicated in the figure. C, mRNA expression of methylated LC3B, ATG5, and ATG7 in different groups indicated in the figure. D, Aza (0.25 mg/kg) and Zeb (200 mg/kg)-treated macrophages derived from NAFLD and treated mice were subjected to Western blotting against DNMT1, β-actin, ATG5, Beclin-1, LC3I/II, β-actin. E, bar graphs represent the densitometric ratio of DNMT1 to the corresponding β-actin. F, bar graphs represent the densitometric ratio of LC3I/II to the corresponding β-actin. G, bar graphs represent the densitometric ratio of ATG5 to the corresponding β-actin. H, bar graphs represent the densitometric ratio of Beclin-1 to the corresponding β-actin. I, transmission electron microscopy images of macrophage derived from Aza (0.25 mg/kg) and Zeb (200 mg/kg)-treated mice indicating upregulation of autophagy (red arrows indicate the autophagosomes formation) compared with NAFLD mice (the scale bar represents 2 μm in CON and NAFLD and 1 μm in Aza [0.25 mg/kg] and Zeb [200 mg/kg]). Data are represented as mean ±SD, ∗∗∗p < 0.001 versus Control group #p < 0.05, ##p < 0.01, and ###p < 0.001 versus NAFLD group. Error bars (wherever applicable in the figure) represent standard deviations from 3 to 6 independent experiments.